Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
_256_384.jpg)
As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The govt has rolled out three schemes for promoting the manufacture of API
Drug formulations and biologics make impressive gains
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
Subscribe To Our Newsletter & Stay Updated
